Two Sigma Advisers LP decreased its holdings in Iradimed Corporation (NASDAQ:IRMD - Free Report) by 26.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,000 shares of the medical equipment provider's stock after selling 13,100 shares during the period. Two Sigma Advisers LP owned about 0.29% of Iradimed worth $2,035,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in IRMD. R Squared Ltd bought a new stake in Iradimed in the 4th quarter valued at $30,000. US Bancorp DE increased its holdings in shares of Iradimed by 476.6% in the fourth quarter. US Bancorp DE now owns 617 shares of the medical equipment provider's stock valued at $34,000 after purchasing an additional 510 shares during the last quarter. Huntington National Bank increased its holdings in shares of Iradimed by 34.0% in the fourth quarter. Huntington National Bank now owns 1,993 shares of the medical equipment provider's stock valued at $110,000 after purchasing an additional 506 shares during the last quarter. State of Wyoming bought a new position in shares of Iradimed in the fourth quarter valued at about $149,000. Finally, Avantax Advisory Services Inc. acquired a new stake in shares of Iradimed during the 4th quarter worth about $217,000. 92.34% of the stock is owned by institutional investors and hedge funds.
Iradimed Price Performance
NASDAQ IRMD traded down $0.09 on Monday, reaching $57.79. The stock had a trading volume of 76,983 shares, compared to its average volume of 43,218. Iradimed Corporation has a 1-year low of $41.69 and a 1-year high of $63.29. The company has a market cap of $734.80 million, a P/E ratio of 38.53 and a beta of 0.91. The firm has a fifty day moving average of $52.50 and a two-hundred day moving average of $54.44.
Iradimed Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, May 30th. Investors of record on Tuesday, May 20th were paid a $0.17 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $0.68 annualized dividend and a dividend yield of 1.18%. Iradimed's dividend payout ratio (DPR) is presently 43.87%.
Analysts Set New Price Targets
IRMD has been the topic of a number of research reports. Wall Street Zen upgraded shares of Iradimed from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, May 6th. Roth Mkm restated a "buy" rating and set a $72.00 price objective (up previously from $60.00) on shares of Iradimed in a report on Friday, February 14th.
Get Our Latest Report on Iradimed
About Iradimed
(
Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Further Reading
Before you consider Iradimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iradimed wasn't on the list.
While Iradimed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
